Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Parkinson's Disease

Free Subscription 01.07.2019 1 BMC Neurol 1 Int J Neurosci 2 J Neural Transm (Vienna) 2 Lancet Neurol 4 Mov Disord 1 Nat Neurosci 1 Nervenarzt 4 PLoS One 1 Proc Natl Acad Sci U S A 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Neurol

1. BORM CDJM, Werkmann M, Visser F, Peball M, et al
   Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional study.
   BMC Neurol. 2019;19:141.
   PubMed     Text format     Abstract available
   
   

   
   Int J Neurosci

2. KALINDERI K, Papaliagkas V, Fidani L
   Pharmacogenetics and levodopa induced motor complications.
   Int J Neurosci. 2019;129:384-392.
   PubMed     Text format     Abstract available
   
   

   
   J Neural Transm (Vienna)

3. SI QQ, Yuan YS, Zhi Y, Wang M, et al
   SNCA rs11931074 polymorphism correlates with spontaneous brain activity and motor symptoms in Chinese patients with Parkinson's disease.
   J Neural Transm (Vienna). 2019 Jun 26. pii: 10.1007/s00702-019-02038.
   PubMed     Text format     Abstract available
   
   
4. RIEDERER P, Berg D, Casadei N, Cheng F, et al
   alpha-Synuclein in Parkinson's disease: causal or bystander?
   J Neural Transm (Vienna). 2019 Jun 25. pii: 10.1007/s00702-019-02025.
   PubMed     Text format     Abstract available
   
   

   
   Lancet Neurol

5. SCHINDLBECK KA, Eidelberg D
   Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease.
   Lancet Neurol. 2019 Jun 19. pii: S1474-4422(19)30242.
   PubMed     Text format    
   
   
6. WILSON H, Dervenoulas G, Pagano G, Koros C, et al
   Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study.
   Lancet Neurol. 2019 Jun 19. pii: S1474-4422(19)30140.
   PubMed     Text format     Abstract available
   
   

   
   Mov Disord

7. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
   No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
   Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27777.
   PubMed     Text format     Abstract available
   
   
8. FERNANDEZ-SANTIAGO R, Martin-Flores N, Antonelli F, Cerquera C, et al
   SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
   Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27770.
   PubMed     Text format     Abstract available
   
   
9. NG ASL, Tan YJ, Zhao Y, Saffari SE, et al
   SNCA Rep1 promoter variability influences cognition in Parkinson's disease.
   Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27768.
   PubMed     Text format     Abstract available
   
   
10. COLLIER TJ, Sortwell CE, Mercado NM, Steece-Collier K, et al
    Cell therapy for Parkinson's disease: Why it doesn't work every time.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27742.
    PubMed     Text format     Abstract available
    
    

    
    Nat Neurosci

11. SHAHMORADIAN SH, Lewis AJ, Genoud C, Hench J, et al
    Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes.
    Nat Neurosci. 2019;22:1099-1109.
    PubMed     Text format     Abstract available
    
    

    
    Nervenarzt

12. BROCKMANN K, Gasser T
    [Personalized treatment of Parkinson's disease].
    Nervenarzt. 2019 Jun 26. pii: 10.1007/s00115-019-0748.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

13. LAN BL, Yeo JHW
    Comparison of computer-key-hold-time and alternating-finger-tapping tests for early-stage Parkinson's disease.
    PLoS One. 2019;14:e0219114.
    PubMed     Text format     Abstract available
    
    
14. MIHAILA D, Donegan J, Barns S, LaRocca D, et al
    The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function.
    PLoS One. 2019;14:e0218252.
    PubMed     Text format     Abstract available
    
    
15. CERESNAK SR, Pass RH, Dubin AM, Yang L, et al
    Validation of a novel automated signal analysis tool for ablation of Wolff-Parkinson-White Syndrome.
    PLoS One. 2019;14:e0217282.
    PubMed     Text format     Abstract available
    
    
16. SAKAI R, Suzuki M, Ueyama M, Takeuchi T, et al
    E46K mutant alpha-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type alpha-synuclein in Drosophila models of Parkinson's disease.
    PLoS One. 2019;14:e0218261.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

17. CZANIECKI C, Ryan T, Stykel MG, Drolet J, et al
    Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.
    Proc Natl Acad Sci U S A. 2019 Jun 24. pii: 1900576116.
    PubMed     Text format     Abstract available
    
    

    
    Rev Neurol (Paris)

18. TRANCHANT C
    Introduction and classical environmental risk factors for Parkinson.
    Rev Neurol (Paris). 2019 Jun 18. pii: S0035-3787(19)30587.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: